Ethnic considerations in pharmacogenetic studies

Journal of Clinical Oncology

Volumn 26, Issue 10, 2008, Pages 1766-1767

  Branford, Ruth A ^a   Pantelidis, Panagiotis ^b   Ross, Joy R ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

DNA POLYMORPHISM; ETHNICITY; GENETIC ASSOCIATION; GENOTYPE; LETTER; OVARY CANCER; PHARMACOGENETICS; PRIORITY JOURNAL; DRUG RESISTANCE; ETHICS; FEMALE; GENETICS; HUMAN; MULTICENTER STUDY; NOTE; OVARY TUMOR; RANDOMIZED CONTROLLED TRIAL;

DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MULTICENTER STUDIES AS TOPIC; OVARIAN NEOPLASMS; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 43249104464     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.5929     Document Type: Letter

References (3)

1. Marsh S, Paul J, King C, et al: pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish randomised trial in ovarian cancer. J Clin Oncol 25:4528-4535, 2007
2. Vasey PA, Jayson GC, Gordon A, et al: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682-1691, 2004
3. Gréen H, Söderkvist P, Rosenberg P, et al: Mdr-1 single neucleotide polymorphism in ovarian cancer tissue: G2677T/A correlates to response to paclitaxel chemotherapy. Clin Cancer Res 12:854-859, 2006